Vaxart (VXRT) announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine ...

The first, an investigational norovirus mRNA vaccine from Moderna (mRNA-1403), safely elicited strong antibody responses in ...

SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

A new trial that aims to protect against norovirus, a highly contagious stomach bug that causes vomiting and diarrhoea, is ...

In a world first, a norovirus vaccine is set to be trialled in the UK. Norovirus is a common bug that causing vomiting and diarrhoea and is easily spread, affecting people of all ages. Due to its ...

A vaccine is to be trialled on thousands of people to find out if it could protect against norovirus - a stomach bug that ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.78 which represents a decrease of $-0.04 or -4.88% from the prior close of $0.82. The stock opened at $0.81 and touched a low of ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

On Monday, Vaxart Inc (VXRT) stock saw a decline, ending the day at $0.77 which represents a decrease of $-0.02 or -2.53% from the prior close of $0.79. The stock opened at $0.79 and touched a low of ...

Apollo (NYSE: APO) today announced the launch of Apollo S3 Private Markets Fund ("ASPM US”) and Apollo S3 Private Markets Lux ("ASPM Lux,” together with ASPM US, "ASPM”), products designed to provide ...

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at ...